Tuberculin Purified Protein Derivative
PreclinicalSmall molecule
Tuberculin Purified Protein Derivative is one of 42 small molecule programs targeting Immunodeficiency. It is currently in Preclinical.
1
Indications
4
Total Trials
0
Active Trials
41
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
46 competitors in Immunodeficiency
#DrugCompanyPhaseTrials
1Fuzeon
CConrado Roberto Hoffmann Filho
Approved
Adenocard
AstellasApproved
Viramune
Boehringer IngelheimApproved
Busulfex
Akero TherapeuticsApproved
Rayos
RRoxane Laboratories
Approved
Cabenuva
GSKPhase 3
Immunoglobulin
SanofiPhase 3
Cytosar
TevaPhase 2
Vepesid
AAvyxa
Phase 2
Bicnu
MMelissa K Accordino
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Immunodeficiency1 trial
Immune Response1 trial
Common Wart1 trial
Efficacy of Cryotherapy Combined With Intralesional Tuberculin PPD Versus Intralesional Tuberculin PPD in Treatment of Multiple Common Warts
Unknown status·—·Phase 3·NCT04288817·40 enrolled
Leprosy1 trial
Leprosy Skin Test Antigens Trial
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00128193·260 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details